BioAtla, Inc. (BCAB)
NASDAQ: BCAB · IEX Real-Time Price · USD
-0.220 (-6.57%)
Apr 12, 2024, 4:00 PM EDT - Market closed

BioAtla Statistics

Total Valuation

BioAtla has a market cap or net worth of $150.54 million. The enterprise value is $41.53 million.

Market Cap 150.54M
Enterprise Value 41.53M

Important Dates

The next estimated earnings date is Thursday, May 9, 2024, after market close.

Earnings Date May 9, 2024
Ex-Dividend Date n/a

Share Statistics

BioAtla has 48.10 million shares outstanding. The number of shares has increased by 22.74% in one year.

Shares Outstanding 48.10M
Shares Change (YoY) +22.74%
Shares Change (QoQ) +0.32%
Owned by Insiders (%) 9.68%
Owned by Institutions (%) 64.77%
Float 33.67M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 2.13
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.11, with a Debt / Equity ratio of 0.03.

Current Ratio 4.11
Quick Ratio n/a
Debt / Equity 0.03
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -110.60% and return on invested capital (ROIC) is -177.33%.

Return on Equity (ROE) -110.60%
Return on Assets (ROA) -75.40%
Return on Capital (ROIC) -177.33%
Revenue Per Employee n/a
Profits Per Employee -$1.90M
Employee Count 65
Asset Turnover n/a
Inventory Turnover n/a


Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -5.44% in the last 52 weeks. The beta is 1.06, so BioAtla's price volatility has been similar to the market average.

Beta (1Y) 1.06
52-Week Price Change -5.44%
50-Day Moving Average 2.80
200-Day Moving Average 2.33
Relative Strength Index (RSI) 50.43
Average Volume (30 Days) 522,208

Short Selling Information

The latest short interest is 5.59 million, so 11.62% of the outstanding shares have been sold short.

Short Interest 5.59M
Short Previous Month 5.13M
Short % of Shares Out 11.62%
Short % of Float 16.59%
Short Ratio (days to cover) 11.56

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -129.69M
Pretax Income -123.46M
Net Income -123.46M
EBITDA -122.24M
EBIT -123.46M
Earnings Per Share (EPS) -$2.58
Full Income Statement

Balance Sheet

The company has $111.47 million in cash and $2.46 million in debt, giving a net cash position of $109.01 million or $2.27 per share.

Cash & Cash Equivalents 111.47M
Total Debt 2.46M
Net Cash 109.01M
Net Cash Per Share $2.27
Equity / Book Value 70.67M
Book Value Per Share 1.47
Working Capital 88.06M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$104.02 million and capital expenditures -$98,000, giving a free cash flow of -$104.11 million.

Operating Cash Flow -104.02M
Capital Expenditures -98,000
Free Cash Flow -104.11M
FCF Per Share -$2.18
Full Cash Flow Statement


Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

BioAtla does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -22.74%
Shareholder Yield -22.74%
Earnings Yield -82.01%
FCF Yield -69.16%

Analyst Forecast

The average price target for BioAtla is $14.50, which is 363.26% higher than the current price. The consensus rating is "Strong Buy".

Price Target $14.50
Price Target Difference 363.26%
Analyst Consensus Strong Buy
Analyst Count 4
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) -21.90%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a


Altman Z-Score n/a
Piotroski F-Score 2